Prospective use of intramuscular triamcinolone acetonide in pseudogout

Douglas W. Roane, Mark D. Harris, Matthew T. Carpenter, David R. Finger, Mark J. Jarek, Jeff A. Alloway, Alan R. Erickson, William E. Venanzi, Timothy J. Drehmer

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective. To prospectively assess the efficacy of intramuscular (im) triamcinolone acetonide in the treatment of pseudogout. Methods. Fourteen patients with crystal proven pseudogout presenting with an acute attack within 5 days of onset were treated with intramuscular triamcinolone acetonide 60 mg and followed for 30 days. Patients with inadequate response were eligible for a 2nd triamcinolone acetonide injection on Day 1-2. Results. Twelve patients had contraindication to nonsteroidal antiinflammatory agents (NSAID). Acute arthritis was monoarticular in 10 patients, and involved 2 or more joints in 4 patients. All patients had good clinical response to triamcinolone acetonide based on restoration of near baseline joint range of motion and joint circumference, and at least 50% improvement in patient and physician global assessment. Major clinical improvement occurred by Day 1-2 (2 patients), Day 3-4 (11 patients), and Day 10-14 (one patient). Six patients required a 2nd triamcinolone acetonide injection on Day 1-2. Toxicities were not observed. Conclusion. im triamcinolone acetonide appears to be safe, well tolerated, and effective in the treatment of pseudogout. It may be a reasonable alternative therapy when NSAID are contraindicated, and for polyarticular attacks where intraarticular corticosteroids are impractical.

Original languageEnglish (US)
Pages (from-to)1168-1170
Number of pages3
JournalJournal of Rheumatology
Volume24
Issue number6
StatePublished - Jun 1 1997

Fingerprint

Chondrocalcinosis
Triamcinolone Acetonide
Non-Steroidal Anti-Inflammatory Agents
Joints
Injections
Complementary Therapies
Articular Range of Motion
Arthritis
Adrenal Cortex Hormones

Keywords

  • Calcium pyrophosphate dihydrate deposition disease
  • Corticosteroids
  • Pseudogout
  • Triamcinolone acetonide

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Roane, D. W., Harris, M. D., Carpenter, M. T., Finger, D. R., Jarek, M. J., Alloway, J. A., ... Drehmer, T. J. (1997). Prospective use of intramuscular triamcinolone acetonide in pseudogout. Journal of Rheumatology, 24(6), 1168-1170.

Prospective use of intramuscular triamcinolone acetonide in pseudogout. / Roane, Douglas W.; Harris, Mark D.; Carpenter, Matthew T.; Finger, David R.; Jarek, Mark J.; Alloway, Jeff A.; Erickson, Alan R.; Venanzi, William E.; Drehmer, Timothy J.

In: Journal of Rheumatology, Vol. 24, No. 6, 01.06.1997, p. 1168-1170.

Research output: Contribution to journalArticle

Roane, DW, Harris, MD, Carpenter, MT, Finger, DR, Jarek, MJ, Alloway, JA, Erickson, AR, Venanzi, WE & Drehmer, TJ 1997, 'Prospective use of intramuscular triamcinolone acetonide in pseudogout', Journal of Rheumatology, vol. 24, no. 6, pp. 1168-1170.
Roane DW, Harris MD, Carpenter MT, Finger DR, Jarek MJ, Alloway JA et al. Prospective use of intramuscular triamcinolone acetonide in pseudogout. Journal of Rheumatology. 1997 Jun 1;24(6):1168-1170.
Roane, Douglas W. ; Harris, Mark D. ; Carpenter, Matthew T. ; Finger, David R. ; Jarek, Mark J. ; Alloway, Jeff A. ; Erickson, Alan R. ; Venanzi, William E. ; Drehmer, Timothy J. / Prospective use of intramuscular triamcinolone acetonide in pseudogout. In: Journal of Rheumatology. 1997 ; Vol. 24, No. 6. pp. 1168-1170.
@article{5464a2f03736468a9283af06c071ecba,
title = "Prospective use of intramuscular triamcinolone acetonide in pseudogout",
abstract = "Objective. To prospectively assess the efficacy of intramuscular (im) triamcinolone acetonide in the treatment of pseudogout. Methods. Fourteen patients with crystal proven pseudogout presenting with an acute attack within 5 days of onset were treated with intramuscular triamcinolone acetonide 60 mg and followed for 30 days. Patients with inadequate response were eligible for a 2nd triamcinolone acetonide injection on Day 1-2. Results. Twelve patients had contraindication to nonsteroidal antiinflammatory agents (NSAID). Acute arthritis was monoarticular in 10 patients, and involved 2 or more joints in 4 patients. All patients had good clinical response to triamcinolone acetonide based on restoration of near baseline joint range of motion and joint circumference, and at least 50{\%} improvement in patient and physician global assessment. Major clinical improvement occurred by Day 1-2 (2 patients), Day 3-4 (11 patients), and Day 10-14 (one patient). Six patients required a 2nd triamcinolone acetonide injection on Day 1-2. Toxicities were not observed. Conclusion. im triamcinolone acetonide appears to be safe, well tolerated, and effective in the treatment of pseudogout. It may be a reasonable alternative therapy when NSAID are contraindicated, and for polyarticular attacks where intraarticular corticosteroids are impractical.",
keywords = "Calcium pyrophosphate dihydrate deposition disease, Corticosteroids, Pseudogout, Triamcinolone acetonide",
author = "Roane, {Douglas W.} and Harris, {Mark D.} and Carpenter, {Matthew T.} and Finger, {David R.} and Jarek, {Mark J.} and Alloway, {Jeff A.} and Erickson, {Alan R.} and Venanzi, {William E.} and Drehmer, {Timothy J.}",
year = "1997",
month = "6",
day = "1",
language = "English (US)",
volume = "24",
pages = "1168--1170",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "6",

}

TY - JOUR

T1 - Prospective use of intramuscular triamcinolone acetonide in pseudogout

AU - Roane, Douglas W.

AU - Harris, Mark D.

AU - Carpenter, Matthew T.

AU - Finger, David R.

AU - Jarek, Mark J.

AU - Alloway, Jeff A.

AU - Erickson, Alan R.

AU - Venanzi, William E.

AU - Drehmer, Timothy J.

PY - 1997/6/1

Y1 - 1997/6/1

N2 - Objective. To prospectively assess the efficacy of intramuscular (im) triamcinolone acetonide in the treatment of pseudogout. Methods. Fourteen patients with crystal proven pseudogout presenting with an acute attack within 5 days of onset were treated with intramuscular triamcinolone acetonide 60 mg and followed for 30 days. Patients with inadequate response were eligible for a 2nd triamcinolone acetonide injection on Day 1-2. Results. Twelve patients had contraindication to nonsteroidal antiinflammatory agents (NSAID). Acute arthritis was monoarticular in 10 patients, and involved 2 or more joints in 4 patients. All patients had good clinical response to triamcinolone acetonide based on restoration of near baseline joint range of motion and joint circumference, and at least 50% improvement in patient and physician global assessment. Major clinical improvement occurred by Day 1-2 (2 patients), Day 3-4 (11 patients), and Day 10-14 (one patient). Six patients required a 2nd triamcinolone acetonide injection on Day 1-2. Toxicities were not observed. Conclusion. im triamcinolone acetonide appears to be safe, well tolerated, and effective in the treatment of pseudogout. It may be a reasonable alternative therapy when NSAID are contraindicated, and for polyarticular attacks where intraarticular corticosteroids are impractical.

AB - Objective. To prospectively assess the efficacy of intramuscular (im) triamcinolone acetonide in the treatment of pseudogout. Methods. Fourteen patients with crystal proven pseudogout presenting with an acute attack within 5 days of onset were treated with intramuscular triamcinolone acetonide 60 mg and followed for 30 days. Patients with inadequate response were eligible for a 2nd triamcinolone acetonide injection on Day 1-2. Results. Twelve patients had contraindication to nonsteroidal antiinflammatory agents (NSAID). Acute arthritis was monoarticular in 10 patients, and involved 2 or more joints in 4 patients. All patients had good clinical response to triamcinolone acetonide based on restoration of near baseline joint range of motion and joint circumference, and at least 50% improvement in patient and physician global assessment. Major clinical improvement occurred by Day 1-2 (2 patients), Day 3-4 (11 patients), and Day 10-14 (one patient). Six patients required a 2nd triamcinolone acetonide injection on Day 1-2. Toxicities were not observed. Conclusion. im triamcinolone acetonide appears to be safe, well tolerated, and effective in the treatment of pseudogout. It may be a reasonable alternative therapy when NSAID are contraindicated, and for polyarticular attacks where intraarticular corticosteroids are impractical.

KW - Calcium pyrophosphate dihydrate deposition disease

KW - Corticosteroids

KW - Pseudogout

KW - Triamcinolone acetonide

UR - http://www.scopus.com/inward/record.url?scp=0030962411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030962411&partnerID=8YFLogxK

M3 - Article

C2 - 9195527

AN - SCOPUS:0030962411

VL - 24

SP - 1168

EP - 1170

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 6

ER -